Credit Suisse Group Increases Natera (NASDAQ:NTRA) Price Target to $70.00

Natera (NASDAQ:NTRA – Get Rating) had its price objective boosted by Credit Suisse Group from $65.00 to $70.00 in a research note released on Wednesday, The Fly reports.

Several other brokerages have also issued reports on NTRA. UBS Group assumed coverage on shares of Natera in a report on Friday, May 5th. They set a buy rating and a $76.00 price target on the stock. Piper Sandler boosted their target price on shares of Natera from $70.00 to $80.00 in a research note on Friday, February 17th. StockNews.com assumed coverage on Natera in a research note on Thursday, March 16th. They issued a sell rating for the company. Morgan Stanley boosted their price objective on Natera from $70.00 to $72.00 and gave the stock an overweight rating in a research report on Thursday, March 2nd. Finally, Raymond James increased their target price on Natera from $58.00 to $68.00 and gave the company an outperform rating in a research report on Friday, March 3rd. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $74.89.

Natera Stock Down 1.0 %

NASDAQ NTRA opened at $51.10 on Wednesday. The business has a fifty day moving average price of $53.75 and a two-hundred day moving average price of $46.19. The stock has a market capitalization of $5.84 billion, a PE ratio of -9.55 and a beta of 1.22. Natera has a fifty-two week low of $29.21 and a fifty-two week high of $59.75. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.90 and a quick ratio of 3.79.

Natera (NASDAQ:NTRA – Get Rating) last announced its quarterly earnings data on Tuesday, May 9th. The medical research company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($1.18) by ($0.05). The business had revenue of $241.76 million for the quarter, compared to the consensus estimate of $227.43 million. Natera had a negative return on equity of 106.67% and a negative net margin of 66.79%. Natera’s quarterly revenue was up 24.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.45) earnings per share. Equities analysts expect that Natera will post -4.15 earnings per share for the current fiscal year.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 40,835 shares of Natera stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $55.00, for a total transaction of $2,245,925.00. Following the transaction, the chief executive officer now directly owns 205,128 shares of the company’s stock, valued at approximately $11,282,040. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Daniel Rabinowitz sold 5,498 shares of Natera stock in a transaction on Tuesday, February 28th. The shares were sold at an average price of $48.94, for a total transaction of $269,072.12. Following the completion of the transaction, the insider now owns 184,699 shares of the company’s stock, valued at $9,039,169.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Steven Leonard Chapman sold 40,835 shares of the business’s stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $55.00, for a total transaction of $2,245,925.00. Following the completion of the transaction, the chief executive officer now owns 205,128 shares in the company, valued at approximately $11,282,040. The disclosure for this sale can be found here. Insiders sold 104,618 shares of company stock worth $5,618,564 over the last three months. Company insiders own 10.27% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Machina Capital S.A.S. acquired a new stake in Natera during the first quarter worth approximately $28,000. Belpointe Asset Management LLC acquired a new stake in shares of Natera during the 4th quarter worth approximately $28,000. OLD Mission Capital LLC bought a new stake in shares of Natera in the 4th quarter valued at $36,000. First Horizon Advisors Inc. lifted its position in shares of Natera by 970.2% during the 3rd quarter. First Horizon Advisors Inc. now owns 1,006 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 912 shares during the period. Finally, Assetmark Inc. boosted its stake in Natera by 50.5% during the third quarter. Assetmark Inc. now owns 1,314 shares of the medical research company’s stock worth $58,000 after acquiring an additional 441 shares in the last quarter. 93.81% of the stock is owned by institutional investors.

Natera Company Profile

(Get Rating)

Natera, Inc is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).